FindTrial
Sign In

The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weight on Reversal of Rocuronium.

The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weights on Reversal of Neuromuscular Blockade in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03381209
Enrollment
60
Registered
2017-12-21
Start date
2017-06-10
Completion date
2017-11-10
Last updated
2017-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Relaxation

Keywords

Sugammadex, morbidly obese patients, bariatric surgery, neuromuscular blockade

Brief summary

The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight, and actual body weight.

Detailed description

The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight, and actual body weight. Reversal Time: time from administration of Sugammadex to train of four (TOF) ratio ≥ 0.9 will be used as primary outcome. Time need for extubation (time from administration of sugammadex to extubation), and duration of stay in post anesthesia care unit (PACU), will be used as secondary outcome.

Interventions

DRUGSugammadex

sugammadex given based on 3 measurements of body weights

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* patients older than 18 years and under 45 years, * body mass index ≥ 40 kg/m2, with indication of bariatric surgery

Exclusion criteria

* Patients with comorbid including: neuromuscular disease, renal impairment, and patients with difficult airway were excluded from this study.

Design outcomes

Primary

MeasureTime frameDescription
Reversal Time5 minutes after sugammadex administrationReversal Time: time from administration of Sugammadex to train of four (TOF) ratio ≥ 0.9 will be used as primary outcome.

Secondary

MeasureTime frameDescription
duration of stay in PACU60 minutes after admission to the PACUperiod of stay in the PACU
Time need for Extubation10 minutes after sugammadex administrationtime from administration of sugammadex to extubation

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026